BioSpace News Archive

C4 Therapeutics (C4T) today announced the appointment of Adam Crystal M.D., Ph.D. as Chief Medical Officer. Dr. Crystal will oversee C4T’s activities relating to the clinical development of the company’s pipeline of targeted protein degraders.

Register at SoundTheAlarm.org Now to Help Save Lives in Your Community

Onkos Surgical, Inc. announced today that it has partnered with Promimic AB, the world’s leading innovator in nano surface modification, to commercialize Promimic’s proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery.

The US Navy Veterans Mesothelioma Advocate says, “Contrary to what you hear on cable TV or see on the Internet the mesothelioma compensation process is contentious, there are asbestos trust funds but the attorneys who protect those trust funds don’t want to pay, or they are only willing to pay as little as possible.

According to Coherent Market Insights, the Global Surgical Lighting System Market was valued at US$ 394.1 million in 2017, and is projected to exhibit a CAGR of 4.4% during the forecast period (2018 – 2026).

Recent signings represent migrations, new customers, and partnership with the Massachusetts Health Collaborative

Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the “XV Taller sobre la enfermedad de Chagas” conference in Barcelona, Spain.

21st Century Oncology (21CO), the largest integrated cancer care network in America, continues to expand its impressive roster of leading physicians as it has announced the signing of Drs. Mohammad Jahanzeb, Raja Mudad, Edgardo S. Santos, Neil Nagovski, and Simon Abi Aad, and the creation of Florida Precision Oncology, a member of the 21CO Dream Team

Implicity, the French leader in remote monitoring of cardiac implantable electronic devices, announces a €4 million fundraising round with the participation of Serena, XAnge, Siparex and CapDecisif Management.

Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.